Objective The Japan Atherosclerosis Society (JAS) has recommended serum lipid management goals (SLMGs) based on the coronary heart disease (CHD) risk classification included in its 2007 guidelines for the diagnosis and prevention of atherosclerotic cardiovascular disease in the Japanese population (JAS GL 2007). The Japan Society of Ningen Dock created a database of subjects receiving annual health examinations at 21 institutes nationwide. Using this database, we evaluated the efficacy of current treatment for patients with dyslipidemia by identifying risk factors for CHD development, based on the JAS recommendations. Methods This multicenter, retrospective study was conducted using data obtained from 21 institutions across Japan. 17,991 adults taking dyslipidemia medications were enrolled. The JAS GL 2007 was used for evaluation. Since the guideline indicated separate goals (secondary prevention for subjects with a prior history of CHD and primary prevention for those with other CHD risk factors), we evaluated the percentages of goals met. The serum low-density lipoprotein cholesterol (LDL-C) levels were calculated using the Friedewald formula. The LDL-C level was measured using a direct homogeneous assay if the triglycerides (TG) level was 400 mg/dL or higher. Results The achievement rates of the SLMGs were as follows: LDL-C, 72.3%; high-density lipoprotein cholesterol (HDL-C), 94.6%; and TG, 69.7%. Conclusion Our results regarding Japanese patients receiving dyslipidemia treatment for CHD prevention identified insufficient reductions in the levels of LDL-C and TG in those at high risk for CHD and suggest the need for more aggressive lipid-lowering therapy.
Introduction
Important risk factors for coronary heart disease (CHD) include hypercholesterolemia (total cholesterol [TC] : ! 220 mg/dL; low-density lipoprotein cholesterol [LDL-C]: ! 140 mg/dL), hypertension, age (men: ! 45 years; women: ! 55 years), diabetes mellitus type 2 (DM-2) and/or impaired glucose tolerance (IGT), smoking, a family history of CHD, decreased serum high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL), obesity, a history of cerebral infarction or arteriosclerosis obliterans and a history of CHD. Major epidemiologic studies have established a statistical correlation between hypercholesterolemia and an increased risk of CHD (1, 2) . The correlation between hypercholesterolemia and the risk of CHD is also supported by the finding that lowering the serum TC and LDL-C levels leads to CHD risk reduction (3, 4) .
In the United States, the National Cholesterol Education Program (NCEP) was promulgated as a set of evidenceJapan Society of Ningen Dock, Academic Committee, Japan, Department of Clinical Health Science, Tokai University School of Medicine, Japan and Mitsui Memorial Hospital, Japanbased guidelines in 1988 (5) . Thereafter, the NCEP underwent two major revisions (in 1993 (6) and 2001 (7)) and was partially revised in 2004 (8) . In 1997, the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Treatment of Hyperlipidemia in Japanese Adults were published (9) . The Japan Lipid Intervention Trial (J-LIT) (10) studied a cohort of >50,000 patients with hypercholesterolemia prescribed lipid-lowering therapy for primary prevention of CHD. The J-LIT found the risk of CHD to be higher when the mean TC concentration was ! 240 mg/dL and the mean LDL-C concentration was ! 160 mg/ dL (10, 11) . The JAS then revised the Diagnosis and Treatment of Hyperlipidemia in Japanese Adults guidelines in 2002 (12) . The guidelines also propose strict regimens to achieve serum lipid management goals (SLMGs) in patients at high risk of CHD.
Despite the JAS recommendations, there is an insufficient consensus among physicians in Japan as to the choice of first-line therapy in patients with hyperlipidemia. In 2007, the JAS revised the Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Disease in Japanese Patients (13) . In these guidelines, LDL-C rather than TC is used to evaluate the cholesterol levels predicting the risk for atherosclerotic disease. In 2012, the JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 were promulgated (14) . In these guidelines, patients with chronic renal disease, a new risk factor for CHD, are classified into Category III, and stratified according to absolute risk assessments.
Several reports have evaluated achievement rates of SLMGs in Japanese patients following the revision of the Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Disease. Teramoto et al. (15) and Kurihara et al. (16) reported the achievement rates of SLMGs for the GL revised in 2002, the latter of whom specifically described results relating to pitavastatin. Teramoto reported the achievement rates of SLMGs for the GL revised in 2007 (17) ; however, that report was limited to the results of atorvastatin.
This study aimed to evaluate the efficacy of current lipidlowering regimens, and to determine the optimal therapeutic strategies for patients with hyperlipidemia by identifying risk factors for CHD development based on the JAS recommendations published in 2007.
Materials and Methods

Study design
This was a cross-sectional, observational study that assessed the percentage of patients in each CHD risk category and the achievement rates of SLMGs based on the JAS guidelines published in 2007 (JAS GL 2007) (13) .
Study population
This multicenter, retrospective study was conducted using data for subjects undergoing annual health examinations at 21 Ningen Dock institutes located throughout Japan in 2009 (18) . The number of subjects was 286,246 (178,377 men and 107,869 women).
This study was designed in compliance with the ethics regulations outlined in the Declaration of Helsinki. Anonymized health records were used for the analysis, and the privacy of the participants was completely protected. This study was approved by the ethics committee of the Japan Society of Ningen Dock.
The patients were assigned a CHD risk category based on the JAS recommendations published in 2007. The patients were classified into two groups: those who had not developed CHD (primary prevention) and those with a history of CHD (secondary prevention). For secondary prevention, an intensive goal for the LDL-C level (<100 mg/dL) was proposed. For primary prevention, in order to prevent CHD in the future, the patients were categorized into low-risk, intermediate-risk and high-risk groups (Categories I, II, and III, respectively) depending on the number of risk factors other than LDL-C. The major coronary risk factors other than the LDL-C level confirmed to date include age, hypertension, diabetes mellitus (including impaired glucose tolerance), smoking and low HDL-C. In the present study, a family history of CHD was not evaluated. Patients with diabetes or cerebral infarction were categorized as Category III risk equivalent even if no other risk factors were present. Arteriosclerosis obliterans was not evaluated in this study. In Category I (low-risk group) cases with no major coronary risk factors, the management goal for the LDL-C level was <160 mg/dL. The goal for Category II (intermediate-risk group) patients with one to two major risk factors was <140 mg/dL, while that for Category III (high-risk group) patients with three or more major coronary risk factors as well as diabetes and/or cerebral infarction was <120 mg/dL.
Anthropometric measurements and blood samples were obtained after overnight fasting in principle. The serum LDL-C levels were calculated using the Friedewald formula (LDL-C = TC-HDL-C-TG/5) (19). The LDL-C level was measured using a direct homogeneous assay if the TG level was 400 mg/dL or higher. Table 1 shows the number of subjects undergoing examinations after stratification according to sex and age. The number of subjects was 286,246 (178,377 men [50.3±10. was higher in men 54 years of age and younger and higher in women 55 years of age and older. Among the 18,904 patients taking dyslipidemia medications, there were 17,991 patients (11,322 men, 6,669 women) whose LDL-C levels were measured with direct homogeneous assays and calculated using the Friedewald formula. Table 2 shows the characteristics of the study patients. The mean age was 56.8 years for the men and 60.8 years for the women. The clinical parameters in the men, with the exception of age, TC, LDL-C (D), LDL-C (F) and HDL-C, were higher than those observed in the women. Overall, the men had greater CHD risks than the women. The rate of high TG levels (400 mg/dL or higher) was 3.3% in the men and 0.4% in the women. Table 3 shows the distribution of the CHD risk factors across the CHD risk categories. The proportion of men with two risks in Category II was 59.2%, which was higher than that of women. Although the proportion of men with three risks in Category III was 44.7%, 8.3% of the patients had more than four risks. Among the women, the proportion of patients with three risks in Category III was 32.5%, while the proportion of patients with more than four risks was lower than that of the men. The proportion of men with two risks in the secondary prevention group was 52.2%, and 24.9% of the patients had more than three risks. Among the women, the proportion of patients with two risks in the secondary prevention group was 47.9%, while the proportion of patients with more than three risks was lower than that of the men. A comparison of the proportions of CHD risk factors in Categories II and III and the secondary prevention group revealed that age was the most frequently observed factor followed by hypertension in both sexes. Table 4 shows the treatment goals and achievement rates of these goals in each CHD risk category with patients stratified according to sex and age. The LDL-C goals were achieved in 75.4% of patients in the primary prevention group (89.5% in Category I, 81.1% in Category II, 62.9% in Category III), and 44.5% of the patients in the secondary prevention group. The achievement rate of the treatment goals in total was 72.3%. Table 5 shows the treatment goals and achievement rates of these goals for HDL-C and TG with patients stratified by sex and age. The achievement rate of the treatment goal for HDL-C was more than 90%, while that for TG was less than 70% for men and women combined.
Results
Discussion
We asked the councilors of the Japan Society of Ningen Dock to share all of their medical health examination data, the so-called "Ningen dock," collected during the years 2008 and 2009 and received data from 21 institutions as the preparatory stage for developing a database (18) . Among the 287,342 subjects who participated in medical health examinations in 2009, subjects who were older than 20 and younger than 80 years of age were analyzed,.
The risk of CHD can be reduced by decreasing the level of cholesterol (1-4, 10, 11 ). Based on these findings, SLMGs are included in the treatment guidelines for CHD prevention in Japan and elsewhere. However, the rates of achieving the SLMGs have been shown to be unsatisfactory worldwide. For example, the Lipid Treatment Assessment Project (20) , a US survey, found that 38% of patients achieved the LDL-C goals recommended in the NCEP ATP II (21) . Thirty-six percent of patients in the Belgian/Luxembourg Survey on Achievement of European Atherosclerosis Society Lipid Goals (22) achieved the LDL-C goals outlined in the recommendations of the European Atherosclerosis Society (23). Table A1 presents a comparison of the rates of LDL-C management goals met in our study and three other Japanese studies (15) (16) (17) . Differences in subject backgrounds included a greater proportion of men and a lower average age in this study. The proportions of subjects in each category were approximately 10% in the secondary prevention group and 5% in Category I, 50% in Category II and 35% in Category III for primary prevention, essentially identical among the studies.
The rates of achieving the LDL-C and TG goals were not satisfactory. In contrast, the rate of achieving the HDL-C goal was satisfactory based on the JAS 2007 attainment goals (13) . The Dyslipidemia International Study (DYSIS), which evaluated 19,196 patients in Europe and Canada consecutively treated for dyslipidemia, found that the LDL-C targets were not reached by 43.3% of those in the highestrisk category, 35.7% of those with two or more risk factors and 16.7% of those with no or only one risk factor (24) based on the NCEP ATP III (7) . Although the LDL-C goals recommended in JAS GL 2002 (12) and JAS GL 2007 (13) are comparable to those outlined in NCEP ATP III (7), the JAS provides more detailed risk categories based on the lipid levels. The NCEP ATP III recommends LDL-Clowering therapy for primary prevention of CHD and a CHD risk classification that includes just two categories: 0-1 coronary risk factor (low to moderate) and ! 2 coronary risk factors (high). Table A2 presents a comparison of the achievement rates for the LDL-C management goals in this and other Japanese studies (15, 16) . The proportions of subjects in each category were approximately 30% to 50% in the secondary prevention group, 90% in Category I, 80% in Category II and 60% in Category III of primary prevention, essentially identical among the studies. It is possible that our results regarding the efficacy of current treatment for patients with dyslipidemia might be better than the nationwide average, since our database included patients receiving medications for dyslipidemia who undertook annual health examinations.
The serum LDL-C levels were calculated using the Friedewald formula in this study. The LDL-C level was measured using a direct homogeneous assay if the TG level was 400 mg/dL or higher. Table A3 shows the treatment goals and achievement rates of these goals in each CHD risk category among 17,595 patients whose TG levels were <400 mg/dL. The LDL-C goals were achieved in 75.3% of patients in the primary prevention group (89.5% in Category I, 81.0% in Category II and 62.4% in Category III) and 44.4% of the patients in the secondary prevention group. The achievement rate of the treatment goals in total was 72.2%.
This study investigated the achievement rates of SLMGs in patients with dyslipidemia receiving medications who undertook annual health examinations at nationwide institutes. Since the majority of the JAS guidelines were revised in 
Conclusion
The results of this study of Japanese patients receiving lipid-lowering therapy for CHD prevention prescribed based on the JAS recommendations identified insufficient reductions in the levels of LDL-C and TG in those at high risk for CHD and suggest the need for more aggressive lipidlowering therapy in such patients.
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